Antimicrobial Activities of Fidaxomicin

被引:66
作者
Goldstein, Ellie J. C. [1 ,2 ]
Babakhani, Farah [3 ]
Citron, Diane M. [1 ]
机构
[1] RM Alden Res Lab, Culver City, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Optimer Pharmaceut Inc, San Diego, CA USA
关键词
IN-VITRO ACTIVITIES; CLOSTRIDIUM-DIFFICILE; OPT-80; AGENTS;
D O I
10.1093/cid/cis339
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be <= 0.001-1 mu g/mL, with a maximum MIC for inhibition of 90% of organisms (MIC90) of 0.5 mu g/mL. Isolates from 2 phase III clinical trials demonstrated that fidaxomicin MICs of baseline isolates did not predict clinical cure, failure, or recurrence of C. difficile infections. No resistance to fidaxomicin developed during treatment in either study, although a single strain recovered from a cured patient had an elevated MIC of 16 mu g/mL at the time of recurrence. For 135 strains, OP-1118, a major metabolite, had an MIC for inhibition of 50% of organisms of 4 mu g/mL and an MIC90 of 8 mu g/mL. Changes in inoculum size (10(2)-10(5) colony-forming units/spot) or cation concentrations of calcium or magnesium appeared to have no effect on fidaxomicin MICs. Fidaxomicin has little or no activity against gram-negative aerobes and anaerobes or yeast.
引用
收藏
页码:S143 / S148
页数:6
相关论文
共 18 条
  • [1] In vitro activity of OPT-80 against clostridium difcile
    Ackermann, G
    Löffler, B
    Adler, D
    Rodloff, AC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2280 - 2282
  • [2] Effects of Inoculum, pH, and Cations on the In Vitro Activity of Fidaxomicin (OPT-80, PAR-101) against Clostridium difficile
    Babakhani, F.
    Seddon, J.
    Robert, N.
    Shue, Y. -K.
    Sears, P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) : 2674 - 2676
  • [3] Babakhani F, 2004, 44 INT C ANT AG CHEM
  • [4] Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
    Babakhani, Farah
    Gomez, Abraham
    Robert, Nikki
    Sears, Pamela
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2011, 60 (08) : 1213 - 1217
  • [5] Babakhani FK, 2007, 47 INT C ANT AG CHEM
  • [6] Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection
    Citron, D. M.
    Babakhani, F.
    Goldstein, E. J. C.
    Nagaro, K.
    Sambol, S.
    Sears, P.
    Shue, Y. -K.
    Gerding, D. N.
    [J]. ANAEROBE, 2009, 15 (06) : 234 - 236
  • [7] CLSI, 2007, M11A7 CLSI
  • [8] Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species
    Credito, KL
    Appelbaum, PC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (11) : 4430 - 4434
  • [9] In vitro activities of OPT-80 and comparator drugs against intestinal bacteria
    Finegold, SA
    Molitoris, D
    Vaisanen, ML
    Song, YL
    Liu, CX
    Bolaños, M
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) : 4898 - 4902
  • [10] Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection
    Goldstein, Ellie J. C.
    Citron, Diane M.
    Sears, Pamela
    Babakhani, Farah
    Sambol, Susan P.
    Gerding, Dale N.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (11) : 5194 - 5199